Beta-adrenergic blocker therapy and the trabecular meshwork

Area of Science:

• Ophthalmology
• Glaucoma Research
• Cell Biology

Background:

• Glaucoma is a leading cause of irreversible blindness.
• Trabecular meshwork (TM) dysfunction is a key factor in primary open-angle glaucoma (POAG).
• Beta-adrenergic blockers (beta-blockers) are commonly used to manage intraocular pressure in glaucoma patients.

Purpose of the Study:

• To investigate whether beta-blocker therapy for glaucoma induces changes in the trabecular meshwork.
• To assess potential underperfusion-related alterations in the TM structure due to beta-blocker use.

Main Methods:

• Utilized transmission electron microscopy to examine the TM in human POAG donor eyes.
• Compared TM extracellular material, lamellar structure, and cell pigmentation across three groups: beta-blocker treated, non-beta-blocker treated, and untreated elevated intraocular pressure.
• Included normal donor eyes as controls.

Main Results:

• No discernible TM changes were observed in eyes treated with beta-blockers.
• Extracellular matrix composition and lamellar morphology were consistent across POAG groups.
• Trabecular cell pigmentation correlated with aqueous flow, appearing more in regions with normal lamellae.

Conclusions:

• Beta-blocker therapy did not demonstrate evidence of causing underperfusion-induced TM changes.
• Findings suggest the existence of preferential aqueous humor outflow pathways within the TM.
• Trabecular cell pigmentation serves as a potential indicator of aqueous flow dynamics.